XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerbowelradiationsmallprior
  Phrases that lowered it: combinationpatients whooxaliplatinevaluate theparticipants
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Keywords listed: 14 (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Sponsor's past trials: 1 (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 6753 (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 21.7% (raises risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors NCT01640665 · started 2012 · scored riskier than 72% of active trials completed
• Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors NCT00613145 · started 2008 · scored riskier than 23% of active trials completed
• Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer NCT03290937 · started 2017 · scored riskier than 74% of active trials completed
• A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors NCT01306630 · started 2010 · scored riskier than 84% of active trials completed
• Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer NCT01661972 · started 2012 · scored riskier than 94% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.